ANGPTL3 and familial hyperaldosteronism: Treatment of FH patients carrying loss-of-function LDLR mutations (HoFH, HeFH, compound FH) with ANGPTL3 mAb for 4 weeks showed remarkable mean reductions of 50% (27 to 61) in LDL and 47% in TG [52].